宁波均普智能制造股份有限公司 独立董事 关于第二届董事会第九次会议相关事项的独立意见 根据《公司法》、《证券法》、《上市公司独立董事规则》等法律法规、规范性文件 以及《宁波均普智能制造股份有限公司章程》、《宁波均普智能制造股份有限公司独立 董事工作制度》等有关规定，作为宁波均普智能制造股份有限公司（下称"公司"）的 独立董事，经审慎分析，我们对公司第二届董事会第九次会议审议的相关事项发表独 立独立意见如下： 郭志明 签署日期： 年 月 日 ______________ （本页无正文，为《宁波均普智能制造股份有限公司独立董事关于第二届董事会第九 次会议相关事项的独立意见》签署页） 杨丹萍 签署日期： 年 月 日 ______________ （本页无正文，为《宁波均普智能制造股份有限公司独立董事关于第二届董事会 第九次会议相关事项的独立意见》签署页） 一、《关于 2023 半年度募集资金存放与实际使用情况的专项报告》的独立意见 公司 2023 年半年度募集资金存放与使用情况符合中国证监会《上市公司监管指 引第 2 号一上市公司募集资金管理和使用的监管要求》和《上海证券交易所科创板上 市公司自律监管指引第 1 号 ...

688306 2023-042 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 宁波均普智能制造股份有限公司（以下简称"公司"或"本公司"）董事 会根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集资 金管理和使用的监管要求》、《上海证券交易所科创板股票上市规则》以及 《上海证券交易所科创板上市公司自律监管指引第1号——规范运作》的相关规 定，就2023年半年度募集资金存放与使用情况作如下专项报告： 一、 募集资金基本情况 （一）实际募集资金金额和资金到账时间 中国证券监督管理委员会于2022年1月18日核发《关于同意宁波均普智能制 造股份有限公司首次公开发行股票注册的批复》（证监许可[2022]125号），公 司获准以首次公开发行方式向社会公众发行人民币普通股（A股）30,707.07万 股，发行价格5.08元/股，募集资金总额为人民币1,559,919,156.00元，扣除各项 发行费用后的实际募集资金净额为人民币1,418,966,238.97元。天健会计师事务 所（特殊普通合伙）对公司本次首次公开发 ...

3.公告显示，经评估机构评估，标的资产市场法下的股东全部价值范围在- 647.5万美元至190.0万美元。请你公司：进一步披露标的资产评估情况，包括但 不限于评估方法选择及合理性，可比对象或可比案例选取标准、合理性及可比 性，相关指标比较修正的计算过程及依据，评估假设及对影响评估特别事项的 考虑（如有）等，并结合前述分析，说明本次资产出售价格是否公允、合理。 4.公告显示，在所有交割条件得到满足或豁免后的3个工作日内，或者在双 方共同商定的其他日期，双方完成交割行为。请你公司：明确披露本次交易生 效的全部前置条件，交易双方约定的交割条件和豁免条件具体情形，相关交割 或豁免条件是否涉及公司债务承担或债权豁免、或有款项支付、承担特定义务 等情形，相关安排会否损害上市公司利益。 5.公告显示，公司及其他子公司与标的资产存在相关往来款项，买卖双方 尚需进一步磋商。请你公司：补充披露相关往来款项的交易对方、款项金额、 形成原因、未来偿还安排、还款方履约能力和履约保障措施，本次交易评估作 价是否考虑该往来款项的影响，避免上市公司因相关应收款项无法按时、全部 收回而利益受损的具体举措。 688306 2023-043 本公 ...

一、 监事会会议召开情况 宁波均普智能制造股份有限公司（以下简称"公司"）第二届监事会第六 次会议于2023年8月24日在公司召开。与会各位监事已知悉与所议事项相关的必 要信息。监事会主席陈波女士主持本次会议，本次会议应出席监事3名，实际出 席监事3名。本次会议的召集和召开程序符合《公司法》和《公司章程》的相关 规定。 688306 2023-041 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 二、 监事会会议审议情况 1. 审议并通过《关于<2023年半年度报告>议案》 表决结果：3票同意，0票反对，0票弃权。 2. 审议并通过《关于公司2023年半年度募集资金存放与使用情况专项报 告的议案》 表决结果：3票同意，0票反对，0票弃权。 特此公告。 宁波均普智能制造股份有限公司监事会 2023年8月25日 ...

688306 2023-038 本公司董事会及全体董事保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 宁波均普智能制造股份有限公司（以下简称"公司"）于2023年8月17日收 到公司董事长周兴宥先生《关于提议宁波均普智能制造股份有限公司以集中竞 价交易方式回购公司股份的函》。提议内容主要如下： 一、提议回购股份的原因和目的 基于对公司未来发展的信心和对公司价值的认可，为建立完善公司长效激 励机制，充分调动公司员工的积极性，有效地将股东利益、公司利益和员工利 益紧密结合在一起，促进公司健康可持续发展，根据相关法律法规，周兴宥先 生提议公司以集中竞价交易方式进行股份回购。回购的股份将全部用于员工持 股及、或股权激励计划，并在发布股份回购实施结果暨股份变动公告后3年内转 让；若公司未能在股份回购实施结果暨股份变动公告后3年内转让完毕，则将依 法履行减少注册资本的程序，未转让股份将被注销。 二、提议内容 1.回购股份的种类及方式：通过上海证券交易所股票交易系统以集中竞价 交易方式回购公司已发行的人民币普通股（A股）股票。 2.回购股份的用途：员工持股及/或股权激励计划。若公司未能在股份回购 ...

证券代码：688306 证券简称：均普智能 宁波均普智能制造股份有限公司 2023 年 7 月投资者关系活动记录表 | --- | --- | |----------------|------------------| | | □特定对象调研 | | 投资者关系活动 | □媒体采访 | | 类别 | □新闻发布会 | | | 现场参观 | | | 其他（电话会议） | 2023 年 7 月 4 日 15:00-16:00 中信证券、浙江潮汐资本、浙江新都控股、浙江广杰投资 2023 年 7 月 13 日 15:00-16:00 参与单位和时间 兴业证券、国寿资产 2023 年 7 月 24 日 10:00-11:00 银华基金 地点 浙江宁波清逸路 99 号 4 号楼 上市公司接待人 投资者关系总监：刘睿 员姓名 1、提问：公司无人自动驾驶相关产线产品业务情况如何？ 回答：公司在自动驾驶的 4D 毫米波雷达/毫米波雷达、激光雷达、线控制 动、线控转向等相关领域，为采埃孚、图达通、博世华域等知名智能驾驶 及 Tier1 提供智能装配与检测生产设备和服务。例如，公司为采埃孚交 投资者关系活动 付了年产能 60 万 ...

证券代码：688306 证券简称：均普智能 宁波均普智能制造股份有限公司 2023 年 5 月投资者关系活动记录表 | --- | --- | --- | --- | |----------------|---------------|-------------|---------------| | | | | 编号：2023-01 | | | □特定对象调研 | □分析师会议 | | | 投资者关系活动 | □媒体采访 | □业绩说明会 | | | 类别 | □新闻发布会 | □路演活动 | | | | 现场参观 | | | 其他（电话会议） 5 月 19 日，北京风炎投资、宏阳投资、乾弘久盛、八尺龙投资、 参与单位名称 君弘资产、川财证券、汇安基金、通商基金、晖鸿基金 5 月 24 日，国盛证券、海富通基金 时间 2023 年 5 月 19 日 11:00-12:00 2023 年 5 月 24 日 14:00-15:00 地点 浙江宁波清逸路 99 号 4 号楼 上市公司接待人 董事长：周兴宥 员姓名 投资者关系总监：刘睿 1、提问：公司主要业务情况？ 回答：公司作为全球布局的智能制造装备供应商，主要从 ...

证券代码：688306 证券简称：均普智能 公告编号:2023-030 宁波均普智能制造股份有限公司 关于参加 2022 年度工业机器人专场集体业绩说明会 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 宁波均普智能制造股份有限公司（以下简称"公司"）已于 2023 年 4 月 20 日发布公司 2022 年年度报告，于 2023 年 4 月 27 日发布公司 2023 年第一季度报 告，为便于广大投资者更全面深入地了解公司 2022 年度以及 2023 年第一季度经 营成果、财务状况，公司参与了由上海证券交易所主办的 2022 年度工业机器人 专场集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者 可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互 动交流。 一、 说明会类型 1 会议线上交流时间：2023年5月31日（星期三）下午 14:00-15:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roads ...

Financial Performance - The company reported a revenue of CNY 218.15 million for Q1 2023, a decrease of 56.47% year-on-year[5]. - The net profit attributable to shareholders was a loss of CNY 45.53 million, representing a decline of 233.34% compared to the previous year[5]. - Total operating revenue for Q1 2023 was ¥218,148,984.76, a decrease of 56.5% compared to ¥501,165,900.68 in Q1 2022[30]. - Net profit for Q1 2023 was a loss of ¥46,185,126.81, compared to a profit of ¥34,150,516.66 in Q1 2022, representing a significant decline[31]. - The company recorded a total comprehensive loss of ¥39,789,317.48 in Q1 2023, compared to a comprehensive income of ¥19,950,704.73 in Q1 2022[32]. - Basic and diluted earnings per share for Q1 2023 were both -¥0.04, compared to ¥0.03 in Q1 2022[32]. Cash Flow - The net cash flow from operating activities was CNY 90.68 million, indicating positive cash inflow despite the loss[6]. - The company reported a net cash inflow from operating activities of ¥90,684,059.09 in Q1 2023, a recovery from a net outflow of ¥81,568,918.05 in Q1 2022[34]. - The net cash flow from investing activities was $103,971,850.25, compared to a net outflow of $453,408,632.83 in the previous period[35]. - The total cash inflow from financing activities was $288,754,569.54, down from $1,699,075,922.54 in the prior period[35]. - The net cash flow from financing activities was $53,406,548.79, significantly lower than $1,498,073,202.63 in the previous period[35]. - The cash and cash equivalents at the end of the period totaled $830,214,775.48, compared to $1,280,016,213.61 at the end of the previous period[35]. - The net increase in cash and cash equivalents was $246,261,244.57, down from $960,735,431.27 in the prior period[35]. - The company reported a cash outflow of $222,410,477.81 for debt repayment, compared to $71,281,268.23 in the previous period[35]. - The company’s cash flow management reflects a strategic focus on maintaining liquidity amid changing market conditions[35]. Research and Development - Research and development expenses totaled CNY 14.61 million, down 40.41% year-on-year, but accounted for 6.70% of revenue, an increase of 1.81 percentage points[6]. - Research and development expenses for Q1 2023 were ¥14,608,064.04, down 29.5% from ¥20,768,764.11 in Q1 2022[31]. - The company has increased its R&D investment in smart equipment, focusing on machine vision inspection technology and next-generation technologies in the fields of new energy vehicles and healthcare[19]. - The company has obtained 2 new invention patents and 7 new utility model patents during the reporting period, bringing the total authorized patents to 137, including 31 invention patents[20]. Orders and Backlog - New orders received in Q1 2023 totaled 424 million RMB, with 349 million RMB (82%) coming from the new energy smart vehicle application sector[17]. - As of the end of the reporting period, the company had a backlog of orders amounting to 3.906 billion RMB[17]. - The company’s new orders and backlog in the smart manufacturing equipment market are growing rapidly, particularly in the new energy vehicle sector[17]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 4.99 billion, reflecting a 3.78% increase from the end of the previous year[6]. - The total current assets as of March 31, 2023, amounted to CNY 3,457,589,284.01, an increase from CNY 3,303,309,602.98 as of December 31, 2022, representing a growth of approximately 4.67%[25]. - The company’s total assets as of March 31, 2023, were CNY 4,989,573,067.89, compared to CNY 4,807,718,045.16 as of December 31, 2022, indicating an increase of approximately 3.78%[26]. - The company’s total current liabilities as of March 31, 2023, were CNY 2,627,681,287.41, an increase from CNY 2,252,598,143.23 as of December 31, 2022, reflecting a growth of approximately 16.66%[26]. Market and Client Impact - The company’s performance is affected by the investment strategies and cycles of major clients, leading to quarterly revenue fluctuations[16]. - The company’s major clients, including ZF, Magna, and Daimler, have adjusted their investment strategies based on industry developments[16]. - The company is leveraging decades of experience in medical health intelligent manufacturing to expand its market presence[17]. - The company delivered various smart equipment, including high-performance electric drives and 800V high-voltage charging boost modules, to major clients such as German luxury car manufacturers and leading suppliers[17]. - The company has made significant technological breakthroughs in the medical intelligent equipment market, particularly in pre-filled injection devices and implantable medical devices[17]. - The company’s clients include well-known international medical device companies, with successful deliveries made by its German subsidiary[17]. Strategic Initiatives - The company expects that the delays in project revenue recognition will not affect the completion of planned projects within the year[6]. - The company has increased its workforce and related expenses to support growth in sectors such as new energy vehicles and healthcare[7]. - The company anticipates normal cash inflows from project repayments, with a healthy cash flow position reported[7]. - The company aims to enhance its competitiveness in overseas markets by leveraging its global collaboration model and the advantages of its subsidiaries[22]. - The company plans to continue expanding its business in both domestic and international markets, particularly in the new energy vehicle sector, to meet the growing demand[22]. - The company is actively exploring the application of artificial intelligence to improve design standardization and manufacturing efficiency in smart equipment[21]. Financial Challenges - Financial expenses increased by 323.13%, primarily due to exchange rate fluctuations impacting foreign currency transactions[11]. - The company experienced a significant decrease in trade receivables, down 98.49% due to the maturity of bank acceptance bills[11]. - The company reported a significant increase in inventory, with total inventory as of March 31, 2023, at CNY 2,097,529,612.13, compared to CNY 1,892,109,229.19 as of December 31, 2022, representing an increase of approximately 10.91%[25]. - The company reported a significant increase in other income to ¥3,226,066.95 in Q1 2023, down from ¥16,079,501.97 in Q1 2022[31].

Financial Performance - The company's operating revenue for 2022 was CNY 1,995,346,697.84, representing a decrease of 6.75% compared to CNY 2,139,823,017.26 in 2021[21]. - The net profit attributable to shareholders for 2022 was CNY 42,276,978.72, a decline of 2.09% from CNY 43,177,242.32 in the previous year[21]. - The net profit after deducting non-recurring gains and losses was CNY 13,934,060.72, which increased by 35.71% compared to CNY 10,267,253.57 in 2021[22]. - The net cash flow from operating activities was negative CNY 229,591,740.45, a significant decrease of 638.83% from CNY 42,609,543.47 in 2021[22]. - The total assets at the end of 2022 were CNY 4,807,718,045.16, an increase of 41.19% from CNY 3,405,170,112.28 in 2021[22]. - The net assets attributable to shareholders increased to CNY 1,987,016,216.09, a substantial rise of 315.49% compared to CNY 478,239,536.25 in 2021[22]. - The average gross profit margin for 2022 was 21.39%, an increase of approximately 3.04 percentage points year-on-year[26]. - The company's basic earnings per share for 2022 was 0.0367 yuan, a decrease of 21.75% from 0.0469 yuan in 2021[23]. - The company reported a net cash outflow of approximately 230 million from operating activities in 2022, driven by the increased demand for cash flow due to the growing order backlog[27]. - The weighted average return on equity decreased to 2.66% in 2022, down 5.99 percentage points from 8.65% in 2021[23]. Orders and Sales - The company achieved a total sales revenue of 1.995 billion in 2022, a decrease of 6.75% compared to the previous year, primarily due to disruptions in import and export logistics and global supply chain tensions[24]. - The company secured new orders worth approximately 2.835 billion in 2022, with the backlog of orders reaching a historical high of 3.684 billion[27]. - New orders in the new energy smart vehicle sector reached 1.102 billion, a significant increase of 73.31% year-on-year, with the backlog in this sector amounting to 1.206 billion, representing 32.73% of total orders[25]. - The company signed new orders worth 2,835 million yuan, representing a year-on-year growth of 29.88%, with a backlog of orders amounting to 3,684 million yuan, up 34.32% year-on-year[40]. Research and Development - Research and development expenses accounted for 3.81% of operating revenue in 2022, slightly up from 3.76% in 2021[23]. - The company has invested significantly in R&D, with a focus on machine vision, intelligent equipment for new energy vehicles, and industrial robots, resulting in a total of 128 authorized patents[39]. - The company achieved a total R&D investment of ¥76,114,861.71 in 2022, a decrease of 5.47% compared to ¥80,520,883.53 in the previous year[89]. - The company holds a total of 128 patents, including 29 invention patents, 96 utility model patents, and 3 design patents[88]. - The company has developed two new core technologies in machine vision and mobile collaborative industrial robots during the reporting period[88]. Market and Industry Trends - The global smart manufacturing market size reached $245.9 billion in 2021 and is projected to grow to $576.2 billion by 2028, with a compound annual growth rate (CAGR) of 12.7% from 2021 to 2028[78]. - In 2022, China's new energy vehicle production and sales reached 7.058 million and 6.887 million units, respectively, representing year-on-year growth of 96.9% and 93.4%, with a market share of 25.6%[78]. - The domestic medical device market is approximately $800 billion, growing at an annual rate of 20%, driven by government procurement policies and the push for domestic alternatives[79]. - The global industrial robot market was valued at approximately $33.9 billion in 2021 and is expected to reach $61.09 billion by 2026, with a CAGR of 12.5%[80]. - The AI industry in China reached a scale of $195.8 billion in 2022, with applications expanding across various sectors including manufacturing[80]. Corporate Governance and Management - The company has established a clear governance structure and effective internal control systems in compliance with regulatory requirements[162]. - The company is committed to complying with the laws and regulations governing listed companies in China[162]. - The management team includes experienced professionals with backgrounds in finance, law, and technology, enhancing the company's strategic capabilities[172]. - The board of directors includes members with extensive experience in various industries, which supports informed decision-making and governance[172]. - The company has a governance structure that ensures checks and balances among its board members[162]. Strategic Initiatives - The company is focused on developing advanced manufacturing technologies and integrating them with new generation information technologies[12]. - The company emphasizes the importance of digital transformation and intelligent manufacturing in its future strategies[12]. - The company aims to deepen cooperation in the fields of new energy vehicles, healthcare, consumer goods, and industrial digitization[48]. - The company plans to leverage its extensive industry experience and data to reduce R&D and manufacturing costs while improving overall equipment performance and value[72]. - The company plans to strengthen market expansion in high-growth sectors such as new energy vehicles, healthcare, and consumer goods, while increasing R&D investment in digital applications[155]. Risks and Challenges - The company has outlined various risks in its operations, which are detailed in the report[4]. - The company faces risks related to project execution, with project cycles typically ranging from 6 to 24 months, which may impact revenue recognition[111]. - The company is exposed to foreign currency translation risks due to its overseas subsidiaries reporting in euros and dollars, while financial data is reported in RMB[112]. - The sales revenue from the top five customers accounted for 53.31% of total sales, indicating a high customer concentration risk[110]. Social Responsibility and Sustainability - The company made a charitable donation of 1.97 million yuan through its overseas subsidiary[196]. - The company has not implemented any carbon reduction measures during the reporting period[196]. - The company has not disclosed any new technologies or products related to carbon reduction[196]. - The company provides comprehensive social insurance for domestic employees, including basic pension, medical, unemployment, maternity, and work injury insurance[199].